Evolus's EPS (Basic) for the
three
months ended in Dec. 2024 was $-0.11.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.81.
Evolus's EPS without NRI for the
three
months ended in Dec. 2024 was $-0.11.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.81.
During the past 3 years, the average EPS without NRIGrowth Rate was 14.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 24.50% per year.
During the past 10 years, Evolus's highest 3-Year average EPS without NRI Growth Rate was 28.60% per year. The lowest was -149.80% per year. And the median was 12.20% per year.
Evolus Earnings per Share (Diluted) Historical Data
The historical data trend for Evolus's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evolus's Earnings per Share (Diluted)
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus's PE Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's PE Ratio distribution charts can be found below:
* The bar in red indicates where Evolus's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Evolus's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Evolus (NAS:EOLS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Evolus Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Evolus's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EOLS has been successfully added to your 